Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) rose 6.3% on Wednesday . The company traded as high as $0.34 and last traded at $0.34. Approximately 1,072,680 shares traded hands during mid-day trading, an increase of 155% from the average daily volume of 421,294 shares. The stock had previously closed at $0.32.
Separately, HC Wainwright set a $6.00 price objective on Ampliphi Biosciences and gave the company a “buy” rating in a report on Friday, August 10th.
Ampliphi Biosciences (NYSEAMERICAN:APHB) last issued its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.01. Ampliphi Biosciences had a negative return on equity of 31.85% and a negative net margin of 2,050.00%.
Ampliphi Biosciences Company Profile (NYSEAMERICAN:APHB)
AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections.
Further Reading: Intrinsic Value and Stock Selection
Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.